The field of cellular senescence has long wrestled with a fundamental problem: not all senescent cells are equal, yet researchers have been treating them as if they were. A unified classification system could transform how we develop senolytics, senomorphics, and targeted aging interventions — and that is precisely what this Perspective in Nature Aging attempts to deliver.
The proposed senotype framework organizes senescent cells according to three defining axes: their cellular origins (the upstream triggers such as DNA damage, oncogene activation, or developmental cues), their molecular fingerprints (transcriptomic, epigenetic, and secretory profiles), and their functional consequences for surrounding tissue — distinguishing adaptive senescence, which serves regenerative or wound-healing roles, from maladaptive senescence, which drives chronic inflammation and tissue dysfunction. Rather than treating senescence as a binary on-off state, the framework maps it as a multidimensional landscape of distinct cell states that can be compared systematically across studies, tissues, and disease contexts.
This conceptual contribution matters considerably for longevity science. The senescence field has been handicapped by inconsistent nomenclature and conflicting findings partly because researchers studying stress-induced senescence in fibroblasts and those studying developmentally programmed senescence in embryonic tissue were effectively describing different phenomena without adequate vocabulary. By analogy, the senotype framework does for senescent cells what cell-type atlases did for immunology — it provides a common coordinate system. The most immediate practical implication is for senolytic drug development: therapies designed to eliminate all senescent cells indiscriminately risk disrupting beneficial adaptive senescent populations. A senotype-aware approach could enable cell-state-specific targeting. Key limitations include this being a Perspective rather than primary data, meaning the framework's utility depends entirely on empirical validation across diverse in vivo models and human tissue samples. It is a conceptual advance — potentially paradigm-shifting in organizing the field, but not yet causal evidence.
